Long-Term Post-Marketing Observational Study of the Safety of Roflumilast
Latest Information Update: 28 Sep 2023
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors AstraZeneca
- 06 Oct 2022 Status changed from recruiting to completed.
- 29 Aug 2022 Planned End Date changed from 31 Jul 2022 to 30 Sep 2022.
- 29 Aug 2022 Planned primary completion date changed from 31 Jul 2022 to 30 Sep 2022.